Clostridium difficile infection: new insights into management
- PMID: 23127735
- PMCID: PMC3541870
- DOI: 10.1016/j.mayocp.2012.07.016
Clostridium difficile infection: new insights into management
Abstract
Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Comment in
-
Clostridium difficile: the emerging epidemic.Mayo Clin Proc. 2012 Nov;87(11):1037-9. doi: 10.1016/j.mayocp.2012.09.004. Mayo Clin Proc. 2012. PMID: 23127729 Free PMC article. No abstract available.
Similar articles
-
Clostridium difficile infection in older adults: a review and update on its management.Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20. Am J Geriatr Pharmacother. 2012. PMID: 22260856 Review.
-
[Individualized treatment strategies for Clostridium difficile infections].Internist (Berl). 2017 Jul;58(7):675-681. doi: 10.1007/s00108-017-0268-2. Internist (Berl). 2017. PMID: 28589214 Review. German.
-
Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.J Hosp Infect. 2015 Jul;90(3):267-70. doi: 10.1016/j.jhin.2015.01.015. Epub 2015 Feb 9. J Hosp Infect. 2015. PMID: 25728208 Clinical Trial.
-
Diagnosis and management of Clostridium difficile infection.Clin Gastroenterol Hepatol. 2013 Oct;11(10):1216-23; quiz e73. doi: 10.1016/j.cgh.2013.03.016. Epub 2013 Mar 28. Clin Gastroenterol Hepatol. 2013. PMID: 23542332 Review.
-
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. doi: 10.1099/mic.0.042010-0. Epub 2010 Aug 19. Microbiology (Reading). 2010. PMID: 20724385 Clinical Trial.
Cited by
-
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29. Clin Microbiol Rev. 2024. PMID: 38421181 Review.
-
Lurking Danger: Emerging Evidence.Indian J Crit Care Med. 2024 Feb;28(2):93-94. doi: 10.5005/jp-journals-10071-24644. Indian J Crit Care Med. 2024. PMID: 38323251 Free PMC article.
-
Clostridioides difficile Infection: A Clinical Review of Pathogenesis, Clinical Considerations, and Treatment Strategies.Cureus. 2023 Dec 27;15(12):e51167. doi: 10.7759/cureus.51167. eCollection 2023 Dec. Cureus. 2023. PMID: 38283489 Free PMC article. Review.
-
Comparative Genomics of Clostridioides difficile.Adv Exp Med Biol. 2024;1435:199-218. doi: 10.1007/978-3-031-42108-2_10. Adv Exp Med Biol. 2024. PMID: 38175477
-
Prevalence of Clostridium Difficile Infection (CDI) among Inflammatory Bowel Disease (IBD) Patients in Comparison to Non-IBD Patients in King Abdulaziz Medical City in Jeddah.Interdiscip Perspect Infect Dis. 2023 Oct 13;2023:9958104. doi: 10.1155/2023/9958104. eCollection 2023. Interdiscip Perspect Infect Dis. 2023. PMID: 37869530 Free PMC article.
References
-
- Bartlett J.G., Chang T.W., Gurwith M., Gorbach S.L., Onderdonk A.B. Antibiotic-associated pseudomembranous colitis due to toxin-producing Clostridia. N Engl J Med. 1978;298(10):531–534. - PubMed
-
- Khanna S., Pardi D.S. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4(4):409–416. - PubMed
-
- Loo V.G., Poirier L., Miller M.A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality [published correction appears in N Engl J Med. 2006;354(20):2200] N Engl J Med. 2005;353(23):2442–2449. - PubMed
-
- Muto C.A., Pokrywka M., Shutt K. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273–280. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
